Lbl-034, a Highly Differentiated T-Cell Engaging Bispecific Antibody Targeting GPRC5D for the Treatment of Relapsed or Refractory Multiple Myeloma

被引：3

作者：

Wang, Baohui ^{[1
]}

Huang, Xiao ^{[1
]}

Sun, Jianming ^{[1
]}

Qin, Yurong ^{[1
]}

Shang, Hongyan ^{[1
]}

Li, Tingting ^{[1
]}

Wu, Guojin ^{[1
]}

Chen, Min ^{[1
]}

Wang, Hailin ^{[1
]}

Zhang, Peng ^{[1
]}

Jiang, Duqing ^{[1
]}

Liu, Tongjun ^{[1
]}

Ye, Mi ^{[1
]}

Cai, Shengli ^{[1
]}

Lai, Shoupeng ^{[1
]}

Kang, Xiaoqiang ^{[1
]}

Ling, Hong ^{[1
]}

机构：

[1] Nanjing Leads Biolabs Co Ltd, Nanjing, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181395

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：2

共 50 条

[31] RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination
Eckmann, Jan
Fauti, Tanja
Zabaleta, Aintzane
Blanco, Laura
Kassem, Sahar
Carrie, Nadege
Lorenz, Stefan
Carpy, Alejandro
Christopeit, Tony
Fertig, Georg
Bernasconi, Luise
Biehl, Marlene
Diggelmann, Sarah
Knobloch, Melanie
Mayoux, Maud
Dumontet, Charles
Paiva, Bruno
Martinet, Ludovic
Leclair, Stephane
Xu, Wei
Klein, Christian
Umana, Pablo
BLOOD, 2022, 140 : 2091 - 2092
[32] Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple Myeloma
Cao, Zhuoxiao
Yang, Cuiqing
Wang, Yifang
Wang, Chao
Wang, Qingyang
Ye, Gang
Liu, Tingting
Wang, Qin
Wang, Huanyu
Gong, Yanxue
Wang, Biye
Jiang, Fuwei
BLOOD, 2022, 140 : 7378 - 7378
[33] A novel T-cell-engaging therapeutical antibody against GPRC5D&BCMA for multiple myeloma treatment
Li, Feng
Wu, Guojin
Peng, Hao
Li, Jiangmei
Qi, Yue
Lin, Guangzhong
Liu, Huifang
Hu, Wenqi
Ning, Jinying
CANCER RESEARCH, 2023, 83 (07)
[34] Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies
Cellerin, Elise
Jourdes, Aurelie
Brousse, Xavier
Vallet, Nicolas
Cartau, Tom
Denis, Blandine
Harel, Stephanie
Jamard, Simon
Redor, Alexis
Cazaubiel, Titouan
Roland, Virginie
Caleteix, Carine
Charles, Morgane
Berger, Pierre
Escure, Guillaume
Collignon, Aude
Faure, Emmanuel
Cazelles, Clarisse
Lanternier, Fanny
Vaux, Clementine De La Porte Des
Frenzel, Laurent
Blot, Mathieu
Danion, Francois
Sonntag, Cecile
Touzeau, Cyrille
Pieragostini, Andrea
Ader, Florence
Karlin, Lionel
Macro, Margaret
Martin-Blondel, Guillaume
Chalopin, Thomas
Perrot, Aurore
BLOOD, 2023, 142
[35] Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report
Bernardi, Chiara
Beauverd, Yan
Tran, Thien An
Maulini, Marie
Mappoura, Maria
Morin, Sarah
Simonetta, Federico
Cairoli, Anne
Auner, Holger W.
Samii, Kaveh
Chalandon, Yves
Ortiz, Carmende Ramon
FRONTIERS IN IMMUNOLOGY, 2024, 15
[36] Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma
Kodama, Tatsushi
Kochi, Yu
Nakai, Waka
Mizuno, Hideaki
Baba, Takeshi
Habu, Kiyoshi
Sawada, Noriaki
Tsunoda, Hiroyuki
Shima, Takahiro
Miyawaki, Kohta
Kikushige, Yoshikane
Mori, Yasuo
Miyamoto, Toshihiro
Maeda, Takahiro
Akashi, Koichi
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (09) : 1555 - 1564
[37] Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
Dekhtiarenko, Iryna
Lelios, Iva
Attig, Jan
Sleiman, Nassim
Lazzaro, Domenico
Schindler, Emilie
Eckmann, Jan
Umana, Pablo
Jacob, Wolfgang
Schneider, Meike
Carlo-Stella, Carmelo
Mazza, Rita
Manier, Salomon
Facon, Thierry
Yoon, Sung-Soo
Koh, Youngil
Harrison, Simon J.
Er, Jeremy
Pinto, Antonio
Volzone, Francesco
Perrone, Giulia
Corradini, Paolo
Cazaubiel, Titouan
Hulin, Cyrille
Touzeau, Cyrille
Moreau, Philippe
Ocio, Enrique M.
Gaisan, Carmen Maria Montes
Popat, Rakesh
Leong, Sarah
Offner, Fritz
Otero, Paula Rodriguez
Alfonso-Pierola, Ana
Hutchings, Martin
Riley, Caroline Hasselbalch
Broske, Ann-Marie E.
BLOOD, 2022, 140 : 10137 - 10139
[38] A novel T cell engager targeting BCMA and GPRC5D showed promising preclinical activity with low toxic risk for multiple myeloma treatment
Fu, Yayuan
You, Shumei
Wei, Menghao
Yin, Bowei
Deng, Qi
Qin, Xiaokang
Zhang, Yun
Wang, Yanqiu
Tang, Renhong
CANCER RESEARCH, 2023, 83 (07)
[39] Preclinical Proof-of-Concept of an mRNA-Based T Cell Engager Targeting BCMA, FcRH5, and GPRC5D for the Treatment of Multiple Myeloma
Garnaas, Maija
Cowens, Kristen
Zhang, Zhen
Deci, Michael
Obana, Maiko
Zielinski, John
Sullivan, Matthew
Karp, Russell
Christainsen, Stephanie
Magliozzi, Brianna
Maclean, Graham
Washington, Terrence
Fu, Ying
Chavada, Varun
D'Ambrosio, Hannah
Singh, Sunil
Eldredge, John
Drombosky, Kenneth
Reddy, Pradeep Babu Jagadeesh
Sharma, Shilpa
Singh, Harkewal
Kaushal, Neeraj
Philip, Binu
Farrington, Graham
Weiss, Brendan M.
Frederick, Joshua P.
Guey, Lin
BLOOD, 2024, 144 : 4163 - 4164
[40] Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies
Nishimura, Noriko
Mailankody, Sham
Nemirovsky, David
Derkach, Andriy
Costa, Bruno Almeida
Farzana, Tasmin
Shaikh, Aisha
Latcha, Sheron
Gutgarts, Victoria
Jurgens, Eric M.
Firestone, Ross S.
Nath, Karthik
Chung, David J.
Landau, Heather J.
Scordo, Michael
Shah, Gunjan L.
Shouval, Roni
Hashmi, Hamza
Hultcrantz, Malin
Korde, Neha
Lesokhin, Alexander M.
Shah, Urvi A.
Tan, Carlyn Rose
Giralt, Sergio A.
Usmani, Saad Z.
Rajeeve, Sridevi
BLOOD, 2024, 144 : 6944 - 6945

← 1 2 3 4 5 →